421 related articles for article (PubMed ID: 11859400)
41. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
[TBL] [Abstract][Full Text] [Related]
42. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
43. Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis.
Goldblum D; Bachmann C; Tappeiner C; Garweg J; Frueh BE
Br J Ophthalmol; 2008 Sep; 92(9):1201-5. PubMed ID: 18650215
[TBL] [Abstract][Full Text] [Related]
44. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
[TBL] [Abstract][Full Text] [Related]
45. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
46. A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation.
Atalla A; Maiolino A; Guimarães MA; Guimarães AC; Nucci M
Braz J Infect Dis; 2005 Aug; 9(4):330-5. PubMed ID: 16270126
[TBL] [Abstract][Full Text] [Related]
47. Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy.
Asbell PA
Trans Am Ophthalmol Soc; 2000; 98():285-303. PubMed ID: 11190029
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir?
Eksborg S; Pal N; Kalin M; Palm C; Söderhäll S
Med Pediatr Oncol; 2002 Apr; 38(4):240-6. PubMed ID: 11920787
[TBL] [Abstract][Full Text] [Related]
49. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older.
Arora A; Mendoza N; Brantley J; Yates B; Dix L; Tyring S
J Infect Dis; 2008 May; 197(9):1289-95. PubMed ID: 18422441
[TBL] [Abstract][Full Text] [Related]
50. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
[TBL] [Abstract][Full Text] [Related]
51. Low-dose oral acyclovir for prevention of herpes simplex virus infection during OKT3 therapy.
Tang IY; Maddux MS; Veremis SA; Bauma WD; Pollak R; Mozes MF
Transplant Proc; 1989 Feb; 21(1 Pt 2):1758-60. PubMed ID: 2652575
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT.
Klein A; Miller KB; Sprague K; DesJardin JA; Snydman DR
Bone Marrow Transplant; 2011 Feb; 46(2):294-9. PubMed ID: 20421867
[TBL] [Abstract][Full Text] [Related]
53. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures.
Miller CS; Cunningham LL; Lindroth JE; Avdiushko SA
J Am Dent Assoc; 2004 Sep; 135(9):1311-8. PubMed ID: 15493396
[TBL] [Abstract][Full Text] [Related]
54. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
[TBL] [Abstract][Full Text] [Related]
55. Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.
Venard V; Dauendorffer JN; Carret AS; Corsaro D; Edert D; Bordigoni P; Le Faou A
Pathol Biol (Paris); 2001 Sep; 49(7):553-8. PubMed ID: 11642018
[TBL] [Abstract][Full Text] [Related]
56. The economic value of valacyclovir prophylaxis in transplantation.
Squifflet JP; Legendre C
J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
[TBL] [Abstract][Full Text] [Related]
57. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir.
Quan D; Hammack BN; Kittelson J; Gilden DH
Arch Neurol; 2006 Jul; 63(7):940-2. PubMed ID: 16682531
[TBL] [Abstract][Full Text] [Related]
58. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing.
Beeson WH; Rachel JD
Dermatol Surg; 2002 Apr; 28(4):331-6. PubMed ID: 11966791
[TBL] [Abstract][Full Text] [Related]
59. [Antiviral therapy adjustment in corneal recipients using antibody testing in the aqueous humor].
Robert PY; Liekfeld A; Ranger-Rogez S; Jaekel C; Pleyer U; Adenis JP; Hartmann C
J Fr Ophtalmol; 2003 Apr; 26(4):350-4. PubMed ID: 12843891
[TBL] [Abstract][Full Text] [Related]
60. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance.
Chakrabarti S; Pillay D; Ratcliffe D; Cane PA; Collingham KE; Milligan DW
J Infect Dis; 2000 Jun; 181(6):2055-8. PubMed ID: 10837192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
